In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.

Novartis CEO Vas Narasimhan stated that the company will not compete in the "frenzy" of the weight loss drug market dominated ...

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".

The CEO of Novartis (NYSE:NVS) said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build ...

Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.

Verzenio was approved for a similar adjuvant indication last year, having been used for a couple of years only in patients ...

Novartis was already riding a wave of momentum with Kisqali, and now it has a new FDA nod to break into the early breast ...

We recently compiled a list of the Top 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...

New CONOPS Details How a VAS Integrates Business, Operational, and Technical Requirements to Support Vertiport Network Proliferation Critical to AAM Success LEHI, UTAH, USA, September 5, 2024 /EINPr..

In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other stocks on Jim Cramer's radar. Jim Cramer often reflects on how he would reform the American ...